Scientists establish new link between pre-eclampsia and diet

Washington, August 26 (ANI): A new study has shown that pregnant women with pre-eclampsia have unusually high levels of a chemical compound called ‘ergothioneine’, which is found in unpasteurised food, in the red blood cells.

The finding made by scientists at the University of Leeds attains significance because they suggest that ergothioneine is an indicator of pre-eclampsia, and may help scientists to understand the cause of the condition, which is currently unknown.

The researchers took blood samples from a group of 37 pregnant women, and compared the red blood cells from women with pre-eclampsia with those from women with no symptoms.

Writing about their findings in the journal Reproductive Sciences, the researchers said that they found a significantly higher concentration of the ergothioneine – a compound made by fungi – in the red blood cells of the women with pre-eclampsia.

Ergothioneine is already well known to be made by micro-organisms that are commonly found in foods like unpasteurised dairy products. Since humans cannot synthesise it, the compound finds its way into human cells exclusively through our diet.

Pregnant women are not advised against eating fungi or foods such as unpasteurised dairy products which contain ergothioneine producing fungi. In fact, scientific studies on animals highlight the benefit of ergothioneine.

“These results suggest that a higher level of ergothioneine is an indicator of pre-eclampsia,” says lead researcher Dr. Julie Fisher, a chemist at the University of Leeds.

“I would not recommend that pregnant women stop eating fungi. However, the high concentration of ergothioneine in the red blood cells of women with pre-eclampsia is a very interesting finding – the more we know about the chemicals involved in the disease the closer we get to understanding what causes it,” says Professor James Walker, Professor of Obstetrics at the Leeds Institute of Molecular Medicine (LIMM), and a co-author of the research.

The symptoms of pre-eclampsia include high blood pressure, protein in urine and fluid retention and affects almost 10 per cent of pregnancies after 20 weeks. If left untreated, the condition can cause a range of problems, such as growth restriction in babies and even foetal and maternal mortality. There is no known cause of the condition.

“Ergothioneine is known as an antioxidant and antioxidants have been proposed to be helpful in reducing the risk of preeclampsia. It is therefore very interesting that we have found it to be in excess for women with the condition,” says Dr. Fisher.

The researchers used a technique that is based on the same science as MRI scans, but which operates on fluids taken from the body, to identify chemicals in the red blood cells of pregnant women.

They say that the amount of these chemicals was found to depend on whether the women were healthy or whether they were suffering from pre-eclampsia.

They previously found that chemical markers for pre-eclampsia also exist in blood plasma. (ANI)

Drug trials point the way to understanding aviation and climate change

Southampton (UK), July 14 (ANI): A unique collaboration between the University of Southampton’s Schools of Engineering Sciences and Medicine, which has presented the most comprehensive review of the impact of aviation on climate this century, has been awarded the Royal Aeronautical Society Silver Medal in London.

The paper entitled ‘Systematic review of the impact of emissions from aviation on current and future climate’ is the first major study of its kind in the last decade, since the Intergovernmental Panel on Climate Change published its findings on this subject in 1999.

Dr Kenji Takeda, Senior Lecturer in the School of Engineering Sciences and lead author of the paper explains: “By using an objective approach to reviewing the effect of aircraft on climate, we hope to provide a good baseline for this active debate. There is a clear need for improving scientific understanding, and it is vital for the aircraft industry to continue to support climate scientists and work towards future solutions for sustainable aviation.”

The Southampton collaboration is unique in the sense that the application of the systematic review methodology for drug appraisals is subject to climate change. The results of the paper show that there is a wide range of predictions for the impact of aviation on climate. These are most dependent on assumptions made about future economic growth. The paper also highlights how dependent we are on the level of scientific understanding and modelling capability, particularly around the non-CO2 effects of aircraft.

Systematic reviews are carried out to identify and synthesise evidence using a transparent and objective approach. They are used extensively by medical researchers for assessing the effectiveness of methods for preventing, treating and managing different diseases, to inform national policy in the UK on their availability across the National Health Service. This is one of the first times this rigorous approach has been applied to the complex issues around climate change. It is hoped that such objective methodology can be more widely applied in this area to help inform and guide the decision-making process that will determine the future of the planet. (ANI)

Cholesterol-busting bug identified

Washington, May 15 (ANI): Scientists at the Universidad Complutense de Madrid, Spain, have discovered a novel species of bacteria with cholesterol-busting properties.

The new bug, called Gordonia cholesterolivorans, was isolated from sewage sludge.

A steroid found in all body tissues, cholesterol is used in the cosmetics and pharmaceutical industries as stabilizer, emollient and water-binding agent.

As a consequence, steroids – including cholesterol – are a major group of contaminants in urban sewage residues.

Gordonia bacteria have only been classed as a separate group of bacteria since 1997 but they have already proved useful as they are able to degrade a wide range of environmental pollutants including phthalates (used in plastics), rubber and hazardous compounds such as the explosive hexogen (cyclotrimethylenetrinitramine).

Gordonia cholesterolivorans’ ability to break down cholesterol means that it could be used to clean up contamination.

Study author Dr Oliver Drzyzga and colleagues are studying the genetics of this novel bacterium to genetically modify strains that might also be used to synthesise new and industrially useful breakdown products of cholesterol.

“New steroid compounds made by these bacteria may find applications in the pharmaceutical and medical sectors in the future, but as some Gordonia species are pathogenic to humans it is unlikely that they could be used directly to treat high cholesterol-related conditions in humans”, said Drzyzga.

“We are trying to work out exactly how Gordonia cholesterolivorans metabolises cholesterol so that we can identify and construct metabolically engineered strains that are more rapid and effective in breaking down cholesterol,” Drzyzga added.

Their findings are reported in the current issue of the International Journal of Systematic and Evolutionary Microbiology. (ANI)

First technique to produce effective anti-leukaemia agent developed

Washington, Apr 18 (ANI): More than a decade after discovering kapakahines- marine-derived natural products with anti-leukaemia potential-scientists have found the first technique to synthesise them in laboratory in large quantities, by using only acetylene gas, a handful of amino acids, and a dozen inventive steps.

Kapakahines were isolated from a South Pacific sponge in trace quantities, but its lack of availability stalled any future studies.

But, thanks to the efforts of researchers at Scripps Research Institute that unlimited production of kapakahine is now possible.

Thus, research on the compound can proceed and may eventually lead to new drug treatments.

Cripbrochalina olemda, a common tube-type sponge like organism, produces a compound called kapakahine B, among other molecules of interest, which has shown potential for fighting leukaemia.

The researchers have said that kapakahine B, which has an unusual structure, uses some never-before-seen mechanism to fight cancer cells.

For a long time, researchers around the world have unsuccessfully tried to devise a method for synthesizing the kapakahines.

Scripps researchers, led by Phil Baran, started on with more basic research, in which they successfully synthesized a simpler related compound, psychotrimine, with no known pharmaceutical potential.

Inspired by this, the researchers created a highly reactive and selective chemical component referred to as a quaternary centre that, because of structural similarities, also drives the essential first step in the kapakahines synthesis.

Later, they set out on a somewhat riskier venture to develop a second stage needed to synthesize kapakahines.

Then, the researchers predicted that using the quaternary centre, they could produce two intermediate isomers, or molecules with the same chemical formula but different structures.

One of the isomers was predicted to be an ideal stepping stone toward the kapakahines, but more difficult to make.

They predicted that the second isomer would be much more reactive, and in theory its concentration would grow sufficiently as it moved toward equilibrium with the first isomer.

And finally, they synthesized two kapakahines for the first time and in gram quantities.

One of the compounds, kapakahine B, has shown potential in fighting leukaemia cells, which could further help in developing potential drug treatment.

The research has been published online by the Journal of the American Chemical Society. (ANI)